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AbstrACt
Introduction Patients undergoing haemodialysis (HD) 
for end-stage kidney disease often report a poor quality 
of life (QoL) and identify that improving QoL has a higher 
priority for them than improvements in long-term survival. 
Research suggests that regular collection and usage of 
patient-reported outcome measures (PROMs) in patients 
with chronic conditions may reduce hospitalisation, 
improve QoL and overall survival. In the UK, despite 
increased use within research settings, PROMs have 
not been introduced into the routine clinical care for 
patients undergoing HD. We report the protocol for 
‘Using patient reported outcome measures (PROMs) to 
promote quality of care in the management of patients 
with established kidney disease requiring treatment with 
haemodialysis in the UK—PROM-HD’. The study aim is 
to investigate the methodological basis for the use of 
routine PROMs assessment, particularly using electronic 
formats (ePROMs) within clinical and research settings, to 
maximise the potential of PROM use in the management of 
the care of this patient group.
Methods and analysis The project will use qualitative 
methodology to explore, by thematic analysis, the views, 
perceptions and experiences of patients receiving HD 
and members of the HD multidisciplinary team regarding 
the collection and use of PROMs in routine clinical care, 
particularly ePROMs. This will involve interviews with up to 
30 patients or until saturation is achieved and three focus 
group sessions with approximately 18 members of the 
clinical team delivering care to this patient group, which 
will be interpreted broadly to include both professional and 
non-professional staff.
IntroduCtIon  
The number of patients with end-stage 
kidney diseases that are being treated with 
renal replacement therapy (RRT) by dialysis 
or transplantation continues to grow. In the 
UK, in December 2015, 61 256 patients were 
receiving RRT, with haemodialysis (HD) being 
used as the treatment modality for 41%1: 
of these 25 114 patients, the large majority 
receive in-centre HD (17.8% hospital, 21.2% 
satellite), 2% receive home HD.1 
Patients receiving maintenance HD often 
experience a significant symptom burden 
associated with their renal failure, both phys-
ical and mental,2–5 and outcomes in terms 
of quality of life (QoL) and survival remain 
poor, even when compared with oncology 
patients.6 7 Traditionally reported outcomes 
such as mortality and progression of kidney 
disease to end-stage kidney disease are estab-
lished indicators of health,8 but it is increas-
ingly recognised that these ‘hard’ outcomes 
strengths and limitations of this study
 ► The use of semistructured interviews and focus 
groups allows a detailed and in-depth examination 
of the issues surrounding the use and implementa-
tion of renal patient-reported outcome measures to 
promote high-quality care in haemodialysis settings.
 ► The iterative approach allows the data collection 
tools to develop and expand as new information 
emerges, and as the data are based on human expe-
rience, it is powerful and possibly more compelling 
than quantitative data on this topic.
 ► The qualitative data arising from this study are 
unlikely to be generalisable, but will inform future 
planned research in this area.
 ► The role of the researcher within the process can 
affect participant responses.
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do not adequately capture patients’ overall QOL and may 
underestimate symptom burden.8 9 While biomedical 
outcomes, such as blood results, are often collected and 
reported during renal care and research, those outcomes 
which focus on well-being and QoL are often deemed 
more important by patients.10 11 Failure to address what 
matters to patients means symptoms and physical prob-
lems can go undetected and therefore untreated,2 12 13 
especially in-between clinic visits,9 and this leads to further 
suffering. Furthermore, patients approaching end-stage 
kidney disease may be willing to trade considerable life 
expectancy to reduce the burdens and restrictions associ-
ated with dialysis affecting QoL.14 15
UK health policy holds patient-centred care and shared 
decision making as a key tenet.16 Patient-centred care 
emphasises, and aligns treatment decisions with, patients’ 
preferences, values and goals.17 This involves a change 
in the philosophy of care from a traditionally passive 
patient role to one where patients are actively involved 
in care planning and problem solving.18 With increased 
prominence being given to patient-centred care and 
shared decision making, the collection of QoL data and 
other patient-reported outcomes (PROs) are becoming 
progressively more important.
PROs are defined as ‘any report of the status of a 
patient’s health condition that comes directly from the 
patient, without interpretation of the patient’s response 
by a clinician or anyone else’.19 Such PROs are most often 
collected using PRO measures (PROMs), self-completed 
questionnaires commonly collating data on general 
QoL and health-related QoL (HRQoL) as well as phys-
ical, emotional and social function, signs or symptoms, 
from the patients’ own point of view.20 Evidence drawn 
from oncology studies suggests that PROMs can offer a 
standardised approach to measuring QoL and symptom 
burden, augmenting clinician understanding of the 
patient’s health status and leading to overall improve-
ments in patient care.21 The mode of administration 
of PROMs has traditionally been in paper format, but 
increasingly they are being completed electronically 
using various digital platforms (ePROMs).
Figure 1 outlines a conceptual framework for PRO 
integration in clinical care taken from Dobrozsi and 
Panepinto.21
While the use of PROMs in routine nephrology practice 
is currently limited, their use in research as measures of 
clinical or treatment effectiveness is more widespread.8 
However, there is no consensus on which PROMs to use 
or their implementation. As part of the international 
Standardised Outcomes in Nephrology Initiative—
Haemodialysis (SONG-HD), major stakeholders have 
been consulted to help develop a core outcome set that 
reflects the priorities of patients, carers and clinicians for 
use in research trials involving HD.7 22 Patients and carers 
placed the highest value on outcomes which allowed 
them to maintain their daily well-being and lifestyle. 
These included the ability to travel, dialysis-free time and 
dialysis adequacy, which was conceptualised broadly as 
dialysis that is adequate for enabling patients to feel well, 
rather than attributable to a biochemical value.7
Initial feedback on the routine use of ePROMs received 
from the USA has focused on some of the perceived and 
experienced challenges in their use, such as increased 
time for completion and IT difficulties. However, with 
increased usage, evidence suggests PRO collection may 
not only enhance clinical care from the patients’ perspec-
tive but may also improve physician satisfaction levels 
and prevent burnout. This is achieved by improvements 
in patient–clinician communication, which may increase 
workflow efficiency.23
While there is evidence to support the use of PROMs 
and particularly ePROMs in the management of patients 
diagnosed with other conditions, such as cancer,24–28 
the evidence for the use and implementation of PROMs 
in the management of patients with end-stage kidney 
disease requiring treatment with HD is currently limited. 
However, although use of PROMs in nephrology research 
studies is increasingly common, standardisation in terms 
of how measures are chosen, implemented and reported 
is lacking. To help address these issues, this study aims to 
provide a rigorous exploration of the acceptability and 
operational feasibility of the collection of routine ePROM 
data with patients undergoing HD, for potential use in 
clinical and research settings.
overall study aim
To explore the feasibility and acceptability of using 
routine PROM assessment, in both clinical and research 
settings, in order to aid the management of patients with 
established renal failure undergoing HD.
Key objectives and key associated questions
1. To investigate the need for PROM use with patients 
and clinicians in HD settings.
 – Do patients and clinicians feel PROM use would be 
beneficial? If so, how might their use alter practice 
and delivery of care?
Figure 1 Conceptual framework for patient-reported 
outcome (PRO) integration in clinical care taken 
from Dobrozsi and Panepinto.21
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 – Would answers to questions differ if PROMs are col-
lected in a research setting, rather than for routine 
clinical practice?
2. To explore the practicalities associated with PROM im-
plementation in HD settings.
 – To assess the optimal timing of collection, that is, 
before or during dialysis sessions, from the patient 
and clinician perspective.
 – To consider the optimal frequency of collection and 
to determine the average length of time required or 
that patients are prepared to spend on completion, 
from the patient and clinician perspective.
 – To gauge the best setting for completion, that is, 
home or clinical area, from the patient and clini-
cian perspective.
 – To determine patients’ ability to self-complete a 
questionnaire successfully and, if not, how much as-
sistance they would require.
 – To examine the feasibility of PROM collection in 
different patient groups (eg, older patients, patients 
of non-white ethnicity).
 – To ascertain the most effective mode of administra-
tion for collection of PRO data, that is, in paper or 
electronic formats, such as mobile application or 
telephone recognition systems, in terms of usability 
and preferences for patients and clinicians.
 – To explore the likely factors (barriers and facilita-
tors) that may improve or discourage the comple-
tion of PROMs by patients and clinicians.
3. To explore the practicalities associated with PROM 
feedback in HD settings.
 – To explore how patients would like to receive feed-
back from the clinical team regarding PRO data.
 – To determine clinicians preferred method of dis-
playing PRO data and the optimum way of provid-
ing patient feedback.
4. To explore the use of existing PROMs with patients in 
HD settings.
 – To explore and determine whether existing validat-
ed PRO measurement tools for example, Kidney 
Disease Quality of Life-Short Form survey (KD-
QOL-SF), Kidney Disease Quality of Life-36-item 
survey (KDQOL-36), Integrated Palliative care Out-
come Scale-Renal (IPOS-Renal) (see table 1) would 
be acceptable to patients undergoing HD and mem-
bers of the renal multidisciplinary team (MDT) 
working within the HD setting for the routine mon-
itoring of patient’s health status.
 – To evaluate the selected PRO questionnaires in 
terms of the relevance of their items and discuss any 
potentially missing items with patient and clinician 
participants.
Methods And AnAlysIs
Project design
This project will use qualitative methods, including semi-
structured interviews and focus groups, to explore the 
experiences and perceptions of patients undergoing HD 
and of clinicians within the MDT caring for these patients.
Project setting
University Hospitals Birmingham NHS Foundation Trust 
will be the host site for this project. Patients who are estab-
lished on HD and are being treated within hospital and 
associated satellite dialysis units will be invited to partic-
ipate in semistructured interviews to explore their views 
and perceptions on the routine use of PROMs. Members 
of the MDT caring for this patient group will be asked to 
participate in focus group sessions to explore their views 
on the use, administration and feedback of PROM data.
Project participants
Participants taking part in the patient interviews must be 
aged ≥18 years old, be able to give valid informed consent 
and be conversant in everyday English. Only patients 
who have been established on HD ≥3 months will be 
interviewed, allowing adjustment to specific issues asso-
ciated with commencement of dialysis. Patients with an 
active intercurrent medical problem, which means they 
require enhanced routine clinical care, will be excluded 
from the study, such as patients who have experienced 
Table 1 Description of questionnaires
Measure Description
Kidney Disease Quality 
of life-36
(KDQOL-36)
A 36-item health-related quality of life (HRQoL) measure designed for patients undergoing dialysis, 
derived from the KDQOL-SF.
Three specific dimensions:
(1) signs and symptoms, (2) burden of kidney disease and (3) effects of kidney disease and a generic 
core derived from the SF-12 (physical and mental scales).
Overall scores range from 0 to 100, with higher scores indicating better HRQoL52–55
Kidney Disease Quality 
of life-SF
(KDQOL-SF)
An 80-item HRQoL measure designed for patients undergoing dialysis which includes the SF-36 
as a generic core (physical and mental scales) supplemented with eight kidney disease-targeted 
dimensions and three additional QoL dimensions.
Scores range from 0 to 100 for each dimension with higher scores indicating better HRQoL52 56 57
Integrated Patient 
Outcome Scale-Renal
(IPOS-Renal)
IPOS-Renal is a short measure (11 questions), combining the most common symptoms renal 
patients experience plus additional items from IPOS on concerns beyond symptoms, such as 
information needs, practical issues, family anxiety33
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a recent episode of acute kidney injury (within the last 
3 months) or have a terminal illness that in the opinion 
of the consultant responsible for routine clinical care is 
likely to lead to the death of the patients within 6 months 
of study participation.
Purposive sampling will be undertaken. Participants 
will be selected for characteristics of relevance to the 
research questions. For example, sampling by ethnicity, 
age, gender and dialysis vintage will be conducted to 
elicit diverse experiences of the phenomenon of interest, 
PROM use in patients receiving HD (maximum variation 
sampling). Every effort will be made to recruit partici-
pants from minority ethnic groups to reflect the broad 
ethnic diversity within a large geographical dialysis catch-
ment area that includes both rural and urban popula-
tions. Recruitment from more than one satellite HD 
unit will ensure that the study reflects the diversity which 
exists within the patient population. Data on participant 
characteristics will be collected as the study progresses in 
order to monitor sample diversity.
Participants invited to take part in MDT focus groups 
must be aged ≥18 years old, be able to give consent and 
be a member of the MDT involved in the care of patients 
undergoing HD at the host site or an associated satellite 
HD unit. The MDT is viewed broadly; therefore, we will 
interview staff with and without membership of profes-
sional bodies and could include doctors, nurses, dieti-
tians, physiotherapists, psychologists, healthcare assistants 
(HCAs) and unit housekeepers. While a highly technical 
clinical specialty, the role of renal HCAs continues to 
expand, and non- professional staff often foster unique 
and close relationships with patients. In other speciali-
ties, HCAs are being directly involved in the assessment 
of outcomes,29 and anecdotally, it is often stated that 
patients will share more, in terms of their experience of 
living with dialysis treatment, than with their nurses and 
doctors. Therefore, the views on the collection and imple-
mentation of renal PROMS by non-professional members 
of the MDT will be sought.
Based on experience from previous similar qualitative 
studies conducted by the research team, recruitment will 
continue until a target sample size of up to 30 patient 
participants is attained or until saturation is achieved. 
Saturation can be described as existing when no new 
codes, themes or categories are emerging from the data 
and the relationships between them can be explained.29
We aim to include up to 18 MDT participants in three 
focus groups (six participants in each group) and, if neces-
sary, follow-up interviews will be conducted, depending 
on emerging data. The focus group sample size has also 
been derived from prior experience of such studies by the 
research team, and recruitment will continue until satu-
ration is reached.
It is recognised that travel to and from dialysis units is a 
significant issue for patients receiving HD. If travel associ-
ated with routine HD appointments is disrupted or likely 
to be disrupted, reasonable travel expenses, that is, taxi 
fare to/from their home address, will be offered so that 
there is as little inconvenience as possible for the patient. 
Likewise, if focus groups are scheduled outside of staff 
members working hours, reasonable travel expenses will 
be made available.
recruitment methods
A member of the renal research team will screen for 
potentially eligible patients using an in-house electronic 
patient records system at the host site, in collaboration 
with members of the dialysis care team. Eligibility will be 
confirmed by a clinician who is on the study delegation 
log. Eligible patients will be sent a study-specific partici-
pant information sheet, which will be discussed further 
in clinic or prior to a dialysis session with a member of 
the research team, where willingness to participate can 
be ascertained. Ethical approval to post information to 
patients following screening but prior to consent has 
been obtained.
Members of the MDT will be approached about study 
participation, and if interested will be provided with a 
focus group information sheet. Those who would like to 
participate will be consented and invited to attend a focus 
group at a mutually convenient time.
Prior to interview or focus group attendance, partici-
pants will be sent copies of selected validated PROMs 
(KDQOL-36, KDQOL-SF and IPOS-Renal, see table 1) 
with instructions to read and review the contents so that 
they are familiar with the form and types of content 
PROMs can take. However, they will be advised that they 
do not need to complete these PROMs, and these are 
samples to assist discussion only.
Recent systematic reviews30 31 have assessed the quality 
of the measurement properties of existing PROMs and 
they recommend the KDQOL-36 for routine clinical prac-
tice and the slightly longer KDQOL-SF for clinical trials/
research purposes in dialysis patients.30
The UK Renal Registry, in response to the growing 
interest in PROMs by the renal community and as part 
of the ‘Valuing Individuals’ and ‘Transforming Participa-
tion in Chronic Kidney Disease (TP-CKD)’ programmes 
has begun piloting the collection of PROM data in the 
form of the generic EuroQol five dimension scale 5-level 
version (EQ-5D-5L) and the disease-specific Palliative care 
Outcome Scale - Symptoms - Renal (POS-S-Renal) ques-
tionnaires.32 The Palliative care Outcome Scale - Renal 
(IPOS-Renal) is a short measure that has been adapted 
from the POS-S-Renal and combines the most common 
symptoms experienced by renal patients with issues such 
as information needs, practical concerns, anxiety or low 
mood, family anxieties and overall feeling of being at 
peace. IPOS has been validated in a mixed population 
of those with cancer and non-cancer diagnosis, including 
renal patients, and shows good content and construct 
validity, reliability and responsiveness to change.33
The IPOS-Renal has been identified by the Renal 
Research Patient Advisory Group as brief and under-
standable and is currently undergoing content validation 
along with the KDQOL-36 in the local renal population 
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as part of the Using Patient-Reported Outcome Measures 
to promote quality of care and safety in the manag-
ment of patients with Advanced Chronic Kidney disease 
(PRO-TRACK) project.30 Therefore, the KDQOL-36, 
KDQOL-SF and IPOS-Renal were selected as the PROMs 
that will be shown and discussed with patients and 
members of the MDT in this qualitative study. There is 
no charge for use from the developers for the KDQOL 
or IPOS-Renal. As the KDQOL-36 is a subset of the 
KDQOL-SF, patients will be asked to consider if the 
shorter PROM is adequate to assess the outcomes which 
matter most, compared with the broader, but longer and 
hence more time consuming to complete KDQOL-SF.
data collection
The guiding qualitative research methodology chosen for 
this study is thematic analysis, as defined by Braun and 
Clarke.34 35 Thematic analysis is a method for identifying, 
analysing and reporting patterns (themes) within data. 
It minimally organises and describes the data set in rich 
detail, also allowing interpretation of various aspects of 
the research topic.35 Patients will be interviewed face-
to-face, or by telephone, to explore their experiences, 
perceptions and views of PROMs. The purpose of the 
focus groups will be to consider the content of selected 
questionnaires in current use with patients receiving HD 
and to discuss the various issues that relate to their use 
and administration. Face-to face or telephone interviews 
with selected staff may be conducted to explore their 
views further.
A topic guide will be used to structure the interviews so 
that all perceived relevant topics are discussed. However, 
there will be scope to digress from the guide if new and 
relevant topics are raised by participants. Analysis of tran-
scripts will be conducted alongside data collection; this 
analysis may shape iterative adjustments to the topic guide 
to ensure all new and emerging topics are fully explored.
Figure 2 demonstrates the participant pathway through 
the study.
data analysis
Analysis of the transcript data will be conducted using 
the Nvivo V.11 software package by QSR International. 
Thematic analysis of the data will be conducted following 
the six-phase guide described by Braun and Clarke.34 35 
The project team will randomly review a sample of coded 
transcripts for verification purposes. Data analysis will 
be carried out simultaneously with data collection and 
both will continue until no new themes emerge from 
the further analysis, that is, data saturation has been 
reached.36 Patient and MDT data will be initially analysed 
separately and then compared for recurrent or unique 
themes. Respondent validation also termed ‘member 
checking’ will be undertaken, whereby a summary of 
the main points arising from the interview will be sent 
to each participant for comments to explore the credi-
bility of the results.37 In order to minimise the challenges 
associated with member checking, such as disagreement 
and distress, we will follow synthesised member-checking 
processes outlined by Birt et al.37
study withdrawal
Study participants who are interviewed will be informed 
that they have the right to freely withdraw from the study, 
for any reason, at any time prior to their data being 
integrated into the data set (ie, within 5 working days 
following their interview). MDT study participants will 
be informed that they have the right to withdraw from 
the study, for any reason, before the focus group session. 
Participants will be reminded at the start of a session 
that, as the focus groups are audio recorded, it will not 
be possible to remove any of their subsequent data once 
the session has commenced due to the nature of evolving 
group discussion. It will be made clear to participants that 
they will not be required to supply a reason for their with-
drawal and the decision will have no effect on either their 
care or terms of employment.
Patient involvement
The study protocol was developed in collaboration with 
members of the Renal Research Patients Advisory Group, 
Centre for Patient-Reported Outcomes Research, Univer-
sity of Birmingham and selected HD patients who gave 
comments and suggestions during the development of 
this project.
Figure 2 Study flow chart diagram. MDT, multidisciplinary team.
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dIsCussIon
The collection of symptom and QoL data through simple 
but validated questionnaires can potentially address the 
problems of underassessing symptom and QoL issues; 
recent studies suggested that ePROM collection may be 
sensitive enough to detect clinically relevant changes and 
could be used to provide ‘early warning’ prompts for 
intervention,38 enhancing and promoting patient engage-
ment and activation in their treatment.39 40 The use of 
ePROMs allows QoL and symptom data to be collected 
remotely and assessed and acted on in ‘real time’,30 with 
research demonstrating that patient reporting may detect 
potentially serious adverse event symptoms earlier than 
traditional clinician reporting.41
Furthermore, the use of PROMs has demonstrated 
substantial improvement in the recognition of prob-
lems which are traditionally underestimated by clinicians 
such as fatigue, pain, emotional and social health when 
compared with control groups.42 There is increasing 
evidence within oncology settings that the collection and 
feedback of PROMs can improve QoL, enrich the commu-
nication between clinician and patient and reduce hospi-
talisations and may improve overall survival.27 28 43
The adequacy of a PROM depends on its characteris-
tics and measurement properties; to be effective, a PROM 
must demonstrate reliability, construct and content 
validity and ability to detect change.30 However, to success-
fully implement the use of selected validated PROMs for 
routine monitoring of health status, it is important to 
consider a wide range of operational issues from both 
patient and clinician perspectives. These include: the 
optimal timing/frequency of PROM data collection, the 
feasibility of PROM collection in different patient groups 
(older patients, patients of non-white ethnicity) and the 
most effective mode of administration for collection of 
PROMs, that is, paper, electronic formats or telephone 
recognition systems.
It is important to consider appropriate recall period, 
and the need to be sure that the patient understands 
what is meant by the recall period. PRO instruments that 
cause patients to rely on their memory, that is, they need 
to recall over a long period of time or which compare 
their current state with an earlier period, or average their 
response over time, can possibly undermine content 
validity. Response is likely to be influenced by the patient’s 
state at the time of recall,19 a factor which must be consid-
ered for patients who receive HD.
Results obtained using PROMs can vary according to 
the instructions given to patients or the training given to 
the interviewer or persons supervising PRO data collec-
tion during a clinical trial.19 There is every reason to 
assume this is true for PRO data collected outside trial 
settings, so it is important to consider how PROMs are 
presented and how clinicians are prepared in terms of 
delivery and feedback mechanisms.
What degree of respondent burden are HD patients 
prepared to tolerate? This will be affected by the length 
and regularity of proposed measures,44 formatting of the 
PROM and questions that patients may feel unwilling 
or uncomfortable in answering; note there is always the 
proviso that patients may refuse to answer any ques-
tions, if they wish. Research suggests that patients with 
lower cognitive function are more likely to report higher 
response burden when completing PRO measures,45 and 
since we know that HD effects cognitive performance,46 
it is important that burden is considered in this clinical 
setting.
Consideration needs to be given to the availability of 
privacy in the setting where the PROM is completed (eg, 
providing a private space for patients to complete or ask 
for assistance in completing questionnaires containing 
sensitive information about their sexual activity or 
substance abuse history, if required).
Most importantly, the timing of measurement needs 
to be considered, that is, ‘when’ in terms of a patient’s 
dialysis regimen. Up to 70% of HD patients over 54 years 
of age may demonstrate cognitive impairment and it has 
been hypothesised that cognitive performance will be 
further impacted by the time point and place of testing.46 
Such fluctuations may be relevant to PROM data collec-
tion. Data from a recent consensus meeting39 suggest 
PROs should preferably not be recorded during dialysis.
A shift from paper PRO collection to ePROMs is 
already evident in other settings.47 The use of ePROM 
capture and feedback needs to be investigated within the 
HD environment. Many HD satellite units are jointly run 
across the National Health Service and private sector, with 
established Electronic Patient Records (EPR) systems that 
could be used to incorporate PROs into their ‘big data’ 
collection. Small studies of home HD and Peritoneal Dial-
ysis (PD) patients suggest that satisfaction with the use of 
tablet computers is high, even with those unused to this 
technology48 but the researchers identified challenges in 
the form of logistics of technology, security, institutional 
and financial support and electronic design.49 Such 
issues will be further explored. However, while qualita-
tive methodology will allow exploration of preferences 
regarding mode of administration and issues around 
technical usability, it is noted that such methodology will 
not explore differences in scores or reliability by mode.
It is important that feedback mechanisms are also 
considered. Inadequate feedback means that outcomes 
reporting will not lead to improvements in patient care. 
By facilitating identification of HRQoL concerns and 
providing a structured way to discuss these, more clin-
ical actions are then taken in response to these identi-
fied needs leading to more responsive and holistic care.50 
There is limited evidence on the feedback of PROMs 
data to MDTs rather than individual doctors and nurses. 
Modern healthcare means it is unlikely that you will see 
the same clinician in a healthcare outpatient setting, 
although it is arguable that regular dialysis sessions do 
offer a degree of continuity compared with other special-
ities. However, it is suggested that PROMs can further 
facilitate MDT decision-making by focusing the team 
on aspects of care central to the patient.51 This aspect of 
 o
n
 5 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021532 on 28 October 2018. Downloaded from 
7Anderson NE, et al. BMJ Open 2018;8:e021532. doi:10.1136/bmjopen-2018-021532
Open access
PROM use will be explored further during the MDT focus 
group sessions.
It is important to consider how operational issues may 
differ in a research setting: would patients and clinicians 
be prepared to undertake a more burdensome regime 
of PRO data collection and how would feedback mech-
anisms and electronic symptom alerts to identify adverse 
events be managed? While the focus of this study is 
around views and perceptions on the acceptability and 
feasibility of routine collection of PROMs in a clinical 
setting, it is important that any nuances around collection 
in a research setting be gathered.
While the evidence for PRO data collection is becoming 
clearer, challenges remain, in the form of how the data 
are collected, interpreted and fed back to patients, both 
within and without research settings. The collection of 
PRO data may involve a shift in workflow, with QoL and 
symptom data potentially being reported in ‘real-time’ 
by patients into their electronic records. There needs to 
be effective mechanisms to respond to these data that 
are not excessively costly or time-consuming.43 The key 
to successful implementation is ‘buy-in’ from patients 
and clinicians and this requires collaboration with all 
stakeholders.
The results from this study will be used to inform 
further research on the implementation of PROMs in 
research and clinical settings, allowing extrapolation to 
other dialysis modalities. As a form of preliminary explo-
ration, qualitative research is invaluable in shaping the 
development of an intervention by exploring its feasi-
bility, acceptability and appropriateness. It is hoped this 
project will contribute to the development and imple-
mentation of PROMs that could enhance QoL assessment 
and hence improve overall QoL for individual patients 
requiring HD as well as improving service delivery and 
patient care.
ethICs And dIsseMInAtIon
This project was approved. It is planned that project find-
ings will be presented at conferences and submitted for 
dissemination via peer-reviewed open access publications. 
Participants will be sent a summary of study findings, if 
they wish.
Acknowledgements The authors would like to thank all members of the Renal 
Research Patients Advisory Group (RRPAG), Centre for Patient-Reported Outcomes 
Research (CPROR), University of Birmingham and selected haemodialysis patients 
for comments and suggestions during the development of this project.
Contributors DK is the guarantor for this project. The project was conceived by 
DK, MC, PC, MD and NEA. NEA drafted the protocol manuscript. The manuscript was 
reviewed by DK, MC, PC, MD and OLA. The final draft was approved by all authors.
Funding This project is funded by the Queen Elizabeth Kidney Patients Association 
(QEKPA): an independent charity working to provide patients with information and 
support with renal matters.
disclaimer The views expressed are the author’s own and not an official position 
of the institution or funder. The researchers are independent from the funders.
Competing interests None declared.
Patient consent Not required.
ethics approval The Gwasanaeth Moeseg Ymchwil (Wales 7) REC(17/WA/0281) 
following proportionate review and Health ResearchAuthority approval on 16 
October 2017.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. MacNeill SJ, Ford D. UK renal registry 19th annual report: chapter 
2 UK renal replacement therapy prevalence in 2015: national and 
centre-specific analyses. Nephron 2017;137(Suppl 1):45–72.
 2. Scherer JS, Combs SA, Brennan F, et al. Sleep disorders, restless 
legs syndrome, and uremic pruritus: diagnosis and treatment 
of common symptoms in dialysis patients. Am J Kidney Dis 
2017;69:117–28.
 3. Lowney AC, Myles HT, Bristowe K, et al. Understanding what 
influences the health-related quality of life of hemodialysis patients: a 
collaborative study in England and Ireland. J Pain Symptom Manage 
2015;50:778–85.
 4. Kraus MA, Fluck RJ, Weinhandl ED, et al. Intensive hemodialysis and 
health-related quality of life. Am J Kidney Dis 2016;68:S33–S42.
 5. Theofilou P. Quality of life in patients undergoing hemodialysis or 
peritoneal dialysis treatment. J Clin Med Res 2011;3:132–8.
 6. Wyld M, Morton RL, Hayen A, et al. A systematic review and meta-
analysis of utility-based quality of life in chronic kidney disease 
treatments. PLoS Med 2012;9:e1001307.
 7. Evangelidis N, Tong A, Manns B, et al. Developing a set of core 
outcomes for trials in hemodialysis: an international delphi survey. 
Am J Kidney Dis 2017;70:464–75.
 8. Aiyegbusi OL, Kyte D, Cockwell P, et al. A patient-centred approach 
to measuring quality in kidney care: patient-reported outcome 
measures and patient-reported experience measures. Curr Opin 
Nephrol Hypertens 2017;26:442–9.
 9. Pakhomov SV, Jacobsen SJ, Chute CG, et al. Agreement between 
patient-reported symptoms and their documentation in the medical 
record. Am J Manag Care 2008;14:530–9.
 10. Nissenson AR. Improving outcomes for ESRD patients: shifting the 
quality paradigm. Clin J Am Soc Nephrol 2014;9:430–4.
 11. Moss AH, Davison SN. How the ESRD quality incentive program 
could potentially improve quality of life for patients on dialysis. Clin J 
Am Soc Nephrol 2015;10:888–93.
 12. Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of 
symptoms in patients on maintenance hemodialysis. Clin J Am Soc 
Nephrol 2007;2:960–7.
 13. Claxton RN, Blackhall L, Weisbord SD, et al. Undertreatment 
of symptoms in patients on maintenance hemodialysis. J Pain 
Symptom Manage 2010;39:211–8.
 14. Morton RL, Tong A, Howard K, et al. The views of patients and 
carers in treatment decision making for chronic kidney disease: 
systematic review and thematic synthesis of qualitative studies. BMJ 
2010;340:c112.
 15. Morton RL, Snelling P, Webster AC, et al. Factors influencing patient 
choice of dialysis versus conservative care to treat end-stage kidney 
disease. CMAJ 2012;184:E277–E283.
 16. Richards T, Coulter A, Wicks P. Time to deliver patient centred care. 
BMJ 2015;350:h530.
 17. Davison SN, Levin A, Moss AH, et al. Executive summary of the 
KDIGO Controversies Conference on Supportive Care in Chronic 
Kidney Disease: developing a roadmap to improving quality care. 
Kidney Int 2015;88:447–59.
 18. Coates V. Role of nurses in supporting patients to self-manage 
chronic conditions. Nurs Stand 2017;31:42–6.
 19. Food and Drug Administration, 2009. Guidance for industry. Patient 
reported outcomes measaures_ Use in medical product development 
to support labelling claims. https://www. fda. gov/ downloads/ drugs/ 
guidances/ ucm193282. pdf (accessed Dec 2017).
 20. Hjollund NH, Larsen LP, Biering K, et al. Use of Patient-Reported 
Outcome (PRO) measures at group and patient levels: experiences 
from the generic integrated PRO System, WestChronic. Interact J 
Med Res 2014;3:e5.
 21. Dobrozsi S, Panepinto J. Patient-reported outcomes in 
clinical practice. Hematology Am Soc Hematol Educ Program 
2015;2015:501–6.
 o
n
 5 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021532 on 28 October 2018. Downloaded from 
8 Anderson NE, et al. BMJ Open 2018;8:e021532. doi:10.1136/bmjopen-2018-021532
Open access 
 22. Urquhart-Secord R, Craig JC, Hemmelgarn B, et al. Patient and 
caregiver priorities for outcomes in hemodialysis: an international 
nominal group technique study. Am J Kidney Dis 2016;68:444–54.
 23. Rotenstein LS, Huckman RS, Wagle NW. Making patients and 
doctors happier - the potential of patient-reported outcomes. N Engl 
J Med 2017;377:1309–12.
 24. Jensen RE, Snyder CF, Abernethy AP, et al. Review of electronic 
patient-reported outcomes systems used in cancer clinical care. J 
Oncol Pract 2014;10:e215–e222.
 25. Bennett AV, Jensen RE, Basch E. Electronic patient-reported 
outcome systems in oncology clinical practice. CA Cancer J Clin 
2012;62:337–47.
 26. Basch E, Snyder C. Overcoming barriers to integrating patient-
reported outcomes in clinical practice and electronic health records. 
Ann Oncol 2017;28:2332–3.
 27. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-
reported outcomes during routine cancer treatment: a randomized 
controlled trial. J Clin Oncol 2016;34:557–65.
 28. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial 
assessing patient-reported outcomes for symptom monitoring during 
routine cancer treatment. JAMA 2017;318:197–8.
 29. Seale C. The quality of qualitative research. London: Sage 
Publications, 2000.
 30. Aiyegbusi OL, Kyte D, Cockwell P, et al. Using Patient-Reported 
Outcome Measures (PROMs) to promote quality of care and safety in 
the management of patients with Advanced Chronic Kidney disease 
(PRO-trACK project): a mixed-methods project protocol. BMJ Open 
2017;7:e016687.
 31. Gibbons E, Fitzpatrick R. A structured review of patient reported 
outcome measures for adults with CKD. Oxford: University of Oxford, 
2010.
 32. (Undated) URRU. Overview of site and work Undated. https://www. 
england. nhs. uk/ wp- content/ uploads/ 2016/ 07/ pa- uk- renal- registry. 
pdf
 33. Palliative Care Outcome Scale, 2017. IPOS-Renal. https:// pos- pal. 
org/ maix/ ipos- renal- in- english. php
 34. Braun V, Clarke V. Succesful qualitative research. London: Sage 
Publications, 2013.
 35. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res 
Psychol 2006;3:77–101.
 36. Fusch P, Ness L. Are we there yet? Data saturation in qualitative 
research. The Qualitative Report 2015;20:1408–16.
 37. Birt L, Scott S, Cavers D, et al. Member Checking: A Tool to Enhance 
Trustworthiness or Merely a Nod to Validation? Qual Health Res 
2016. doi: 10.1177/1049732316654870. [Epub ahead of print 22 Jun 
2016].
 38. Pittman ZC, John SG, McIntyre CW. Collection of daily patient 
reported outcomes is feasible and demonstrates differential patient 
experience in chronic kidney disease. Hemodial Int 2017;21:265–73.
 39. Breckenridge K, Bekker HL, Gibbons E, et al. How to routinely collect 
data on patient-reported outcome and experience measures in renal 
registries in Europe: an expert consensus meeting. Nephrol Dial 
Transplant 2015;30:1605–14.
 40. Schougaard LM, Larsen LP, Jessen A, et al. AmbuFlex: tele-patient-
reported outcomes (telePRO) as the basis for follow-up in chronic 
and malignant diseases. Qual Life Res 2016;25:525–34.
 41. Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes 
to improve the predictive accuracy of clinician-reported adverse 
events. J Natl Cancer Inst 2011;103:1808–10.
 42. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-
of-life assessments and patient-physician communication: a 
randomized controlled trial. JAMA 2002;288:3027–34.
 43. Basch E. PRO's - Harnessing patient voices to improve clinical care. 
N Engl J Med 2017;376:105–8.
 44. Senders A, Hanes D, Bourdette D, et al. Reducing survey burden: 
feasibility and validity of PROMIS measures in multiple sclerosis. 
Mult Scler 2014;20:1102–11.
 45. Atkinson TM, Schwartz CE, Goldstein L, et al. How much is too 
much? predictors of patient response burden in the completion of 
patient-reported outcome assessments. Quality of Life Research 
2017;26(Suppl 1):47–8.
 46. Tholen S, Schmaderer C, Kusmenkov E, et al. Variability of cognitive 
performance during hemodialysis: standardization of cognitive 
assessment. Dement Geriatr Cogn Disord 2014;38:31–8.
 47. eRAPID, 2017. eRAPID Towards safer delivery and monitoring of 
cancer treatments. Electronic patient self-Reporting of Adverse-
events (AE): Patient Information and aDvice. http:// pogweb. org/ 
index. php/ erapid/
 48. Schick-Makaroff K, Molzahn A. Brief communication: patient 
satisfaction with the use of tablet computers: a pilot study in 
two outpatient home dialysis clinics. Can J Kidney Health Dis 
2014;1:22.
 49. Schick-Makaroff K, Molzahn A. Strategies to use tablet computers 
for collection of electronic patient-reported outcomes. Health Qual 
Life Outcomes 2015;13:2.
 50. Etkind SN, Daveson BA, Kwok W, et al. Capture, transfer, and 
feedback of patient-centered outcomes data in palliative care 
populations: does it make a difference? A systematic review. J Pain 
Symptom Manage 2015;49:611–24.
 51. Greenhalgh J. The applications of PROs in clinical practice: what are 
they, do they work, and why? Qual Life Res 2009;18:115–23.
 52. Peipert JD, Hays RD. Methodological considerations in using patient 
reported measures in dialysis clinics. J Patient Rep Outcomes 
2017;1.
 53. Aiyegbusi OL, Kyte D, Cockwell P, et al. Measurement properties of 
patient-reported outcome measures (PROMs) used in adult patients 
with chronic kidney disease: a systematic review protocol. BMJ 
Open 2016;6:e012014.
 54. Peipert JD, Bentler PM, Klicko K, et al. Psychometric properties 
of the Kidney Disease Quality of Life 36-Item Short-Form Survey 
(KDQOL-36) in the United States. Am J Kidney Dis 2018;71.
 55. Peipert JD, Bentler P, Klicko K, et al. Negligible impact of differential 
item functioning between Black and White dialysis patients on 
the Kidney Disease Quality of Life 36-item short form survey 
(KDQOL-36). Qual Life Res 2018:2699–707.
 56. Aiyegbusi OL, Kyte D, Cockwell P, et al. Measurement properties 
of patient-reported outcome measures (PROMs) used in adult 
patients with chronic kidney disease: A systematic review. PLoS One 
2017;12:e0179733.
 57. Hays RD, Kallich JD, Mapes DL, et al. Kidney Disease Quality of 
Life Short Form (KDQOL-SFTM) Version 1.3: A manual for use and 
scoring. Santa Monica, CA: Rand, 1995. Contract No.: P-7994.
 o
n
 5 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021532 on 28 October 2018. Downloaded from 
